Raymond James Financial
ABOS icon

Raymond James Financial’s Acumen Pharmaceuticals ABOS Stock Holding History

Raymond James Financial’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-495
Closed -$574 – 4964
2025
Q2 		$574 Buy
+495
New +$532 ﹤0.01% 6657

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Raymond James Financial's ABOS Position: Q3 2025 in Review

Raymond James Financial sold out of Acumen Pharmaceuticals (ABOS) in Q3 2025, closing a stake of 495 shares — an estimated $574 sold.

Raymond James Financial first reported a position in ABOS in Q2 2025 and held it in 1 quarter. The position peaked at $574 in Q2 2025. 69 funds tracked by Wall St. Rank hold ABOS as of Q3 2025.

  • Raymond James Financial reported no remaining Acumen Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 495 Acumen Pharmaceuticals shares in Q3 2025, an estimated $574.
  • Raymond James Financial first reported a position in Acumen Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Acumen Pharmaceuticals position peaked at $574 in Q2 2025.
  • 69 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.